in vitro News and Research

RSS

Cellix expands European distribution network with Tebu-bio

Cellix are pleased to announce the signing of a distribution agreement with tebu-bio SAS. tebu-bio has a well-established pan-European presence, recognised by the international scientific community with local offices in France, Germany, Belgium, the Netherlands, Italy, Denmark, Portugal, Spain and the UK.

11 Apr 2011

New dengue test receives FDA marketing clearance

The U.S. Food and Drug Administration today allowed marketing of the first test to help diagnose people with signs and symptoms of dengue fever or dengue hemorrhagic fever, a leading cause of illness and death in the tropics and subtropics.

11 Apr 2011

Cepheid receives FDA clearance for new assay to detect C. difficile infection

The U.S. Food and Drug Administration today cleared a test called the Cepheid Xpert C. difficile/Epi assay that is designed to rapidly detect the toxin B gene associated with Clostridium difficile infection, a cause of diarrhea that can lead to colitis, other serious intestinal conditions and death in severe cases.

11 Apr 2011

Polaris' ADI-PEG 20 exhibits potential against AML, GBM and bladder cancer

Polaris Group announced today that data from preclinical studies suggest ADI-PEG 20, the Company's pegylated arginine deiminase therapeutic, may be effective in treating acute myeloid leukemia (AML), glioblastoma multiforme (GBM) and bladder cancer.

8 Apr 2011

Caffeine disrupts glucose metabolism and may contribute to type 2 diabetes

A growing body of research suggests that caffeine disrupts glucose metabolism and may contribute to the development and poor control of type 2 diabetes, a major public health problem.

8 Apr 2011

Scientists identify two molecules that enable cancer spread

For many types of cancer, the original tumor itself is usually not deadly. Instead, it's the spread of a tiny subpopulation of cells from the primary tumor to other parts of the body—the process known as metastasis—that all too often kills the patient.

8 Apr 2011

Luminex receives Medical Design Excellence Award for innovative MAGPIX system

Luminex Corporation has won a 2011 Medical Design Excellence Award in the category of In Vitro Diagnostics for its innovative MAGPIX system. Introduced in 2010, MAGPIX is a compact, versatile laboratory analysis platform designed to improve productivity by delivering multiple highly accurate, reproducible results from a single sample.

From Luminex 8 Apr 2011

FDA to discuss 2008 immunogenicity directives with European industry experts at Pharma IQ

This May, Joao Pedras-Vasconcelos, Visiting Associate, Therapeutic Proteins CBER from FDA will meet with European industry experts at Pharma IQ's to discuss FDA directives on immunogenicity introduced in 2008.

6 Apr 2011

Specific lipids in tumours linked to cancer progression and patient survival

Activation of lipid metabolism is an early event in carcinogenesis and a central hallmark of many cancers. However, the precise molecular composition of lipids in tumours remains generally poorly characterised. Scientists from VTT Technical Research Centre of Finland and the Charité Hospital have found lipids in tumours which are associated with cancer progression.

6 Apr 2011

Keryx KRX-0401 data in colorectal cancer, multiple myeloma presented at AACR meeting

Keryx Biopharmaceuticals, Inc. today announced that two posters on KRX-0401 were presented at the 102nd annual meeting of the American Association for Cancer Research currently ongoing at the Orange County Convention Center in Orlando, Florida. Perifosine, the Company's novel, potentially first-in-class, oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase pathway, is currently in Phase 3 clinical trials for refractory advanced colorectal cancer and multiple myeloma.

6 Apr 2011

Study finds low multiple birth rates in 15 states that provide insurance coverage for IVF

Faced with the prospect of costly in vitro fertilization but with no help from insurance coverage, some infertile couples feel pressure to transfer multiple embryos in an attempt to ensure that the IVF is a success.

6 Apr 2011

Adipocytes associated with breast cancer could amplify 'aggressive' effect of tumors in obese patients

Apart from its direct effect on health (such as cardiovascular diseases and diabetes), obesity is increasingly suspected of playing a role in the prognosis of breast cancer and, in particular, its propensity to spread. However, no direct cause and effect relationship had been demonstrated until now. This breakthrough has finally been made through the collaborative work of two teams of researchers from Inserm, CNRS and the Université Paul Sabatier.

6 Apr 2011

Caliper's CDAS unit enters cancer research collaboration with Denver-based CHI

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life-sciences research, today announced that its Caliper Discovery Alliances and Services unit has formed a research collaboration with Denver-based Catholic Health Initiatives, one of the nation's largest health systems.

6 Apr 2011

ARIAD's ponatinib potently inhibits all four FGFRs abnormally expressed in multiple cancers

ARIAD Pharmaceuticals, Inc. today announced results of preclinical studies on ponatinib, its investigational pan-BCR-ABL inhibitor, showing potent inhibition of all four members of the fibroblast growth factor receptor (FGFR) family of tyrosine kinases that are abnormally expressed in multiple cancers. ARIAD scientists are presenting the data this morning at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

5 Apr 2011

Aeterna Zentaris presents two posters on perifosine at AACR meeting

Aeterna Zentaris Inc. today announced that two posters on its lead anticancer agent, perifosine, were presented at the 102nd annual meeting of the American Association for Cancer Research currently held at the Orange County Convention Center in Orlando, Florida.

5 Apr 2011

Synta presents ganetespib and elesclomol study data in cancer at AACR meeting

Synta Pharmaceuticals Corp. today presented five posters at the American Association for Cancer Research 102nd Annual Meeting. Three posters reported results from studies of ganetespib, and two posters reported results from studies of elesclomol, a small-molecule mitochondria metabolism inhibitor.

5 Apr 2011

Scientists discover new compounds that may help fight against parasitic diseases

Trypanosomatid parasites cause diseases like African sleeping sickness, Chagas' disease and leishmaniasis. Leishmaniasis affects about 12 million people worldwide, mostly in developing countries. Current drug treatments are inadequate due to drug toxicity and resistance.

5 Apr 2011

Vermillion, Quest Diagnostics enter agreement to launch OVA1 IVDMIA assay in India

Vermillion, a molecular diagnostics company, today announced that it has signed an agreement with Quest Diagnostics to make OVA1 available in India. The companies are targeting a launch in the second quarter of 2011. Additionally, at the International Gynecologic Cancer Society (IGCS) regional meeting held in New Delhi April 2-3, 2011, Dr. Fred Ueland presented data demonstrating the high sensitivity for ovarian malignancy of OVA1 in combination with ultrasound.

From Quest Diagnostics 4 Apr 2011

ImmunoGen presents IMGN529 data against NHL, CLL at AACR meeting

ImmunoGen, Inc., a biotechnology company that develops targeted antibody-based anticancer products using its antibody expertise and Targeted Antibody Payload technology, today disclosed the profile and first preclinical data for the Company's novel IMGN529 product candidate for the treatment of B-cell malignancies including non-Hodgkin's lymphoma and chronic lymphocytic leukemia.

4 Apr 2011

Study demonstrates in vitro infection and HEV replication in human hepatocytes

Groundbreaking data presented today demonstrates, for the first time, in vitro infection and replication of swine hepatitis E virus in human hepatocytes.

4 Apr 2011